European drugmakers say that at least as far as they are concerned, Japan is beginning to reap the benefits from its drug regulator's faster process of reviewing and approving drug applications. The head of the European Federation of Pharmaceutical Industries and Associations also applauded the changes in the "innovation premium" of Japan's Pharmaceutical and Medical Devices Agency (PMDA) pricing system that makes it more attractive to sell in Japan. Chairman Carsten Brunn said in an interview with EURObiz Japan that together the changes are also a boon to Japan, where 10% of the world's top 100 drugs that have not been available to patients are now entering the local market. FiercePharmaAsia story | Subscribe